Perspective Therapeutics (CATX) Other financing activities (2010 - 2026)
Perspective Therapeutics' (CATX) quarterly Other financing activities came in at $160000.0 in Q2 2026, up 10.34% year-over-year from $145000.0 in Q2 2025, and down 44.83% quarter-over-quarter from $290000.0 in Q1 2026.
Powered by 
Analysis
Perspective Therapeutics (CATX) Other financing activities (2010 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Other financing activities across 14 years of filings, most recently posting $160000.0 for Q2 2026.
- In Q2 2026, Other financing activities rose 10.34% year-over-year to $160000.0; the TTM figure through Jun 2026 stood at $676000.0 (down 40.91% YoY), while the FY2025 annual figure was $371000.0, down 70.39% from the prior year.
- Other financing activities came in at $160000.0 for Q2 2026 at Perspective Therapeutics, down from $290000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $642000.0 in Q3 2024 to a low of $22000.0 in Q3 2023.
- Average Other financing activities over 5 years is $223833.3, with a median of $152500.0 recorded in 2025.
- The largest YoY upside for Other financing activities was 2818.18% in 2024 against a maximum downside of 75.94% in 2024.
- Over 5 years, Other financing activities stood at $30000.0 in 2022, then dropped by 26.67% to $22000.0 in 2023, then surged by 1522.73% to $357000.0 in 2024, then slumped by 36.69% to $226000.0 in 2025, then dropped by 29.2% to $160000.0 in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were $160000.0 in Q2 2026, $290000.0 in Q1 2026, and $226000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 160,000.00 |
| Mar 31, 2026 | 290,000.00 |
| Sep 30, 2025 | 226,000.00 |
| Jun 30, 2025 | 145,000.00 |
| Dec 31, 2024 | 357,000.00 |
| Sep 30, 2024 | 642,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 126,000.00 |
| Sep 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 532,000.00 |
| Dec 31, 2022 | 30,000.00 |
| Sep 30, 2022 | 28,000.00 |
| Dec 31, 2021 | 28,000.00 |
| Jun 30, 2021 | 16,000.00 |
| Mar 31, 2021 | 7.78 Mn |
| Jun 30, 2019 | 13,000.00 |
| Dec 31, 2016 | 2,000.00 |
| Mar 31, 2016 | 3,000.00 |
| Sep 30, 2015 | 47,000.00 |
| Jun 30, 2015 | 68,726.00 |